Multiple sclerosis: a complicated picture of autoimmunity

被引:793
作者
McFarland, Henry F. [1 ]
Martin, Roland
机构
[1] NINDS, NIH, Neuroimmunol Branch, Bethesda, MD 20892 USA
[2] Univ Med Ctr Eppendorf, Ctr Mol Neurobiol Hamburg, Inst Neuroimmunol, D-20251 Hamburg, Germany
[3] Univ Med Ctr Eppendorf, Ctr Mol Neurobiol Hamburg, Clin Multiple Sclerosis Res, D-20251 Hamburg, Germany
关键词
D O I
10.1038/ni1507
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Understanding of autoimmune diseases, including multiple sclerosis, has expanded considerably in recent years. New insights have been provided by not only animal models but also studies of patients, often in conjunction with experimental therapies. It is accepted that autoimmune T cells mediate the early steps of new multiple sclerosis lesions, and although uncertainties remain about the specific targets of autoreactive T cells, several studies indicate myelin antigens. Recent findings obtained with both animal models and patients with multiple sclerosis indicate involvement of a T helper cell with a T-H-17 phenotype, in contrast to previous data indicating that T helper type 1 cells are critical. Evidence has also been presented for CD8(+) and regulatory T cell populations, although their involvement remains to be established. Despite evidence supporting the idea that autoreactive T cells are involved in disease induction, cells of myeloid lineage, antibodies and complement as well as processes intrinsic to the central nervous system seem to determine the effector stages of tissue damage. Careful analysis of the alterations in immune processes should further advance knowledge of the relationship between the inflammatory component of this disease and the more diffuse degeneration of progressive multiple sclerosis.
引用
收藏
页码:913 / 919
页数:7
相关论文
共 89 条
[1]   Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells [J].
Acosta-Rodriguez, Eva V. ;
Napolitani, Giorgio ;
Lanzavecchia, Antonio ;
Sallusto, Federica .
NATURE IMMUNOLOGY, 2007, 8 (09) :942-949
[2]   Pathological abnormalities in the normal-appearing white matter in multiple sclerosis [J].
Allen, IV ;
McQuaid, S ;
Mirakhur, M ;
Nevin, G .
NEUROLOGICAL SCIENCES, 2001, 22 (02) :141-144
[3]   IL-1β regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program [J].
Argaw, Azeb Tadesse ;
Zhang, Yueting ;
Snyder, Brian J. ;
Zhao, Meng-Liang ;
Kopp, Natalya ;
Lee, Sunhee C. ;
Raine, Cedric S. ;
Brosnan, Celia F. ;
John, Gareth R. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (08) :5574-5584
[4]   Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment [J].
Avolio, C ;
Filippi, M ;
Tortorella, C ;
Rocca, MA ;
Ruggieri, M ;
Agosta, F ;
Tomassini, V ;
Pozzilli, C ;
Stecchi, S ;
Giaquinto, P ;
Livrea, P ;
Trojano, M .
MULTIPLE SCLEROSIS, 2005, 11 (04) :441-446
[5]   Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction [J].
Babbe, H ;
Roers, A ;
Waisman, A ;
Lassmann, H ;
Goebels, N ;
Hohlfeld, R ;
Friese, M ;
Schröder, R ;
Deckert, M ;
Schmidt, S ;
Ravid, R ;
Rajewsky, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (03) :393-404
[6]   Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years [J].
Bagnato, F ;
Jeffries, N ;
Richert, ND ;
Stone, RD ;
Ohayon, JM ;
McFarland, HF ;
Frank, JA .
BRAIN, 2003, 126 :1782-1789
[7]   CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ TH-17 cells in relapsing EAE [J].
Bailey, Samantha L. ;
Schreiner, Bettina ;
McMahon, Eileen J. ;
Miller, Stephen D. .
NATURE IMMUNOLOGY, 2007, 8 (02) :172-180
[8]   Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event [J].
Berger, T ;
Rubner, P ;
Schautzer, F ;
Egg, R ;
Ulmer, H ;
Mayringer, I ;
Dilitz, E ;
Deisenhammer, F ;
Reindl, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02) :139-145
[9]   Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].
Bielekova, B ;
Goodwin, B ;
Richert, N ;
Cortese, I ;
Kondo, T ;
Afshar, G ;
Gran, B ;
Eaton, J ;
Antel, J ;
Frank, JA ;
McFarland, HF ;
Martin, R .
NATURE MEDICINE, 2000, 6 (10) :1167-1175
[10]   Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].
Bielekova, B ;
Catalfamo, M ;
Reichert-Scrivner, S ;
Packer, A ;
Cerna, M ;
Waldmann, TA ;
McFarland, H ;
Henkart, PA ;
Martin, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946